Literature DB >> 28674222

Small suitability of the DLEC1, MLH1 and TUSC4 mRNA expression analysis as potential prognostic or differentiating markers for NSCLC patients in the Polish population.

Jacek Kordiak1, Karolina H Czarnecka, Dorota Pastuszak-Lewandoska, Adam Antczak, Monika Migdalska-Sęk, Ewa Nawrot, Daria Domańska-Senderowska, Justyna Kiszałkiewicz, Ewa Brzeziańska-Lasota.   

Abstract

According to the latest data, lung cancer is one of the most common cancer worldwide, men contributing nearly 21.2% and women 8.6% of all diagnosed cancers. Late detection of tumour drastically reduces the chance for a cure. Thus, it is important to search for candidate biomarkers for screening of early stage nonsmall cell lung carcinoma (NSCLC). Tumour suppressor genes, DLEC1, TUSC4 and MLH1, localized on 3p21 are recognized to play a role in NSCLC carcinogenesis. The aim of this study was to assess the relationship between the DLEC1, TUSC4 and MLH1 mRNA expression, and clinical features of NSCLC patients, tobacco addiction, and tumour histopathological characteristics. The DLEC1, TUSC4 and MLH1 expression was analysed in lung tumour tissue samples obtained from 69 patients diagnosed with NSCLC: squamous cell carcinoma (n = 34), adenocarcinoma (n = 24), large cell carcinoma (n = 5), carcinoma adenosquamosum (n = 5). A decreased gene expression (RQ < 0.7) was observed for DLEC1 in 60.9% of tumour samples, for MLH1 in 50.7% and for TUSC4 in 26% of NSCLC samples. DLEC1 was decreased in more aggressive subtypes: large cell carcinoma and adenocarcinoma-squamous cell carcinoma. The simultaneous downregulation of two of the studied genes, DLEC1 andMLH1,was observed in 30.4% of NSCLCsamples, highlighting the importance of these two genes in lung carcinogenesis. We found no correlation between the DLEC1, TUSC4 and MLH1 gene expression and NSCLC patient characteristics (gender, age and smoking) or cancer histopathology. No significant differences in the gene expression among NSCLC subtypes indicate the weakness of DLEC1, TUSC4 and MLH1 expression analysis as potential differentiating markers of NSCLC subtypes in the Polish population.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28674222     DOI: 10.1007/s12041-017-0770-2

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  22 in total

1.  The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.

Authors:  Kentaro Ueda; Hiroyuki Kawashima; Shoichiro Ohtani; Wu-Guo Deng; Murali Ravoori; Jim Bankson; Boning Gao; Luc Girard; John D Minna; Jack A Roth; Vikas Kundra; Lin Ji
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

2.  Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.

Authors:  Naobumi Tochigi; Sanja Dacic; Marina Nikiforova; Kathleen M Cieply; Samuel A Yousem
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

3.  Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.

Authors:  Youwei Zhang; Yufeng Miao; Jun Yi; Rui Wang; Longbang Chen
Journal:  Clin Lung Cancer       Date:  2010-07-01       Impact factor: 4.785

4.  [Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer].

Authors:  E A Anedchenko; A A Dmitriev; G S Krasnov; T T Kondrat'eva; E P Kopantsev; T V Vinogradova; M V Zinov'eva; I B Zborovskaia; B E Polotskiĭ; O V Sakharova; V I Kashuba; E R Zabarovskiĭ; V N Senchenko
Journal:  Mol Biol (Mosk)       Date:  2008 Nov-Dec

5.  Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C.

Authors:  Jingfeng Li; Fuli Wang; Klas Haraldson; Alexey Protopopov; Fuh-Mei Duh; Laura Geil; Igor Kuzmin; John D Minna; Eric Stanbridge; Eleonora Braga; Vladimir I Kashuba; George Klein; Michael I Lerman; Eugene R Zabarovsky
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 6.  Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers.

Authors:  Eugene R Zabarovsky; Michael I Lerman; John D Minna
Journal:  Oncogene       Date:  2002-10-07       Impact factor: 9.867

7.  Analysis of epidemiological cohort data on smoking effects and lung cancer with a multi-stage cancer model.

Authors:  H Schöllnberger; M Manuguerra; H Bijwaard; H Boshuizen; H P Altenburg; S M Rispens; M J P Brugmans; P Vineis
Journal:  Carcinogenesis       Date:  2006-01-12       Impact factor: 4.944

Review 8.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

9.  Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population.

Authors:  Xin Geng; Fei Wang; Liang Zhang; Wei Ming Zhang
Journal:  Tumori       Date:  2009 Jul-Aug

Review 10.  Evaluation of the 3p21.3 tumour-suppressor gene cluster.

Authors:  L B Hesson; W N Cooper; F Latif
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  2 in total

1.  Upregulation of HOXA1 promotes tumorigenesis and development of non‑small cell lung cancer: A comprehensive investigation based on reverse transcription-quantitative polymerase chain reaction and bioinformatics analysis.

Authors:  Yu Zhang; Xiao-Jiao Li; Rong-Quan He; Xiao Wang; Tong-Tong Zhang; Yuan Qin; Rui Zhang; Yun Deng; Han-Lin Wang; Dian-Zhong Luo; Gang Chen
Journal:  Int J Oncol       Date:  2018-04-16       Impact factor: 5.650

2.  Clinical value of MLH1-negative circulating tumor cells in lung cancer patients.

Authors:  Jin-Yan Liang; Qi-Fan Yang; Yu-Lan Zeng; Yang-Yang Liu; Yu-Ting Liu; Fei-Fei Gu; Yue Hu; Kai Zhang; Hao Zhong; Li Liu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.